Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific MeetingGlobeNewsWire • Thursday
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 StudyBenzinga • 09/09/24
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual MeetingGlobeNewsWire • 09/05/24
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/04/24
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024GlobeNewsWire • 09/01/24
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024GlobeNewsWire • 09/01/24
Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion OpportunitiesSeeking Alpha • 08/13/24
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in FocusZacks Investment Research • 08/09/24
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/25/24
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewsWire • 07/03/24
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese ParticipantsGlobeNewsWire • 06/17/24